Literature DB >> 8726000

Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

M G Davidson1, M R Lappin, J R Rottman, M B Tompkins, R V English, A T Bruce, J Jayawickrama.   

Abstract

Cats were experimentally inoculated parenterally with the ME49 strain of Toxoplasma gondii to characterize the efficacies of two different dosages of orally administered clindamycin hydrochloride in the treatment of ocular toxoplasmosis. Concentrations of clindamycin hydrochloride at levels previously suggested to be inhibitory to T. gondii replication in vitro were achieved in the serum and aqueous humor but not in the cerebrospinal fluid. Antibiotic therapy, initiated 7 days after inoculation, resulted in no significant difference in the morphometric severity of ocular posterior segment lesions compared with that in the control groups. Treatment appeared to blunt T. gondii-specific immunoglobulin M production but had no significant effect on immunoglobulin G titers. Paradoxically, clindamycin administration was associated with increased morbidity and mortality from hepatitis and interstitial pneumonia, which are characteristic of generalized toxoplasmosis. Serum tumor necrosis factor alpha activity was detected at moderate levels in all groups of cats and correlated with the severity of clinical disease. The results of the study suggest that clindamycin, when administered at this specific time interval following inoculation, does not ameliorate ocular lesions and has a detrimental effect on the clinical course of acute, experimental toxoplasmosis in cats. The factors responsible for and the relevance of this detrimental effect to naturally occurring toxoplasmosis in humans and pet cats were not clear from the study but may relate to an antibiotic-associated decrease in the antitoxoplasmic activity of phagocytic cells responsible for the control of T. gondii.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726000      PMCID: PMC163330          DOI: 10.1128/AAC.40.6.1352

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

Review 1.  Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature.

Authors:  R M Levy; D E Bredesen; M L Rosenblum
Journal:  J Neurosurg       Date:  1985-04       Impact factor: 5.115

2.  Parasiticidal activity of macrophages against Toxoplasma.

Authors:  S D Sharma; J R Catterall; J S Remington
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors:  F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

4.  New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.

Authors:  D G Mack; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

6.  Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys.

Authors:  J S Harper; W T London; J L Sever
Journal:  Am J Trop Med Hyg       Date:  1985-01       Impact factor: 2.345

7.  Clindamycin in the treatment of toxoplasmic retinochoroiditis.

Authors:  V Lakhanpal; S S Schocket; V S Nirankari
Journal:  Am J Ophthalmol       Date:  1983-05       Impact factor: 5.258

8.  Clindamycin in a murine model of toxoplasmic encephalitis.

Authors:  J M Hofflin; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  In vitro assessment of antimicrobial agents against Toxoplasma gondii.

Authors:  C Harris; M P Salgo; H B Tanowitz; M Wittner
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

10.  Interferon-gamma: the major mediator of resistance against Toxoplasma gondii.

Authors:  Y Suzuki; M A Orellana; R D Schreiber; J S Remington
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

View more
  6 in total

Review 1.  Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage.

Authors:  Liise-Anne Pirofski; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

3.  Experimental Models of Ocular Infection with Toxoplasma Gondii.

Authors:  Agata Dukaczewska; Roberto Tedesco; Oliver Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-12-04

Review 4.  Lower respiratory tract infections in cats: reaching beyond empirical therapy.

Authors:  Susan F Foster; Patricia Martin
Journal:  J Feline Med Surg       Date:  2011-05       Impact factor: 2.015

Review 5.  The cat with neurological manifestations of systemic disease. Key conditions impacting on the CNS.

Authors:  Marc Kent
Journal:  J Feline Med Surg       Date:  2009-05       Impact factor: 2.015

6.  Systematic Review of the Pharmacological Evidence for the Selection of Antimicrobials in Bacterial Infections of the Central Nervous System in Dogs and Cats.

Authors:  Robert Hertzsch; Angelika Richter
Journal:  Front Vet Sci       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.